Cancelling mRNA studies is the highest irresponsibility
By Editors,
Nature
| 08. 15. 2025
The rest of the world is not following the US government’s dangerous path, and will stick with the technology that helped the world out of the COVID-19 pandemic.
A technology that played a key part in saving millions of lives during the COVID-19 pandemic1 should be feted to the skies. Instead, US health secretary Robert F. Kennedy Jr announced last week that the US federal government is terminating 22 grants worth nearly US$500 million for projects researching messenger RNA (mRNA) vaccines.
This is the technology that, in his first term (2017–21), US President Donald Trump included in Operation Warp Speed: the federal government’s $18-billion programme to procure COVID-19 vaccines for US populations in record time2. It is also the technology that is showing potential for treating cancers3, autoimmune diseases and inherited conditions such as sickle cell disease. But now, in a statement accompanying the grant cancellations, Kennedy stated that “these vaccines fail to protect effectively against upper respiratory infections like COVID and flu”. And in an article for The Washington Post, Jay Bhattacharya, director of the US National Institutes of Health, wrote that mRNA technology “failed to earn the public’s trust”, which fuelled vaccine hesitancy.
Shock and disbelief does not even begin...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 06.30.2026
A research program at the National Institutes of Health released the world’s largest database of human genomes and paired them with clinical data, officials announced Tuesday, paving the way for a new era of study in personalized medicine.
The All...
By Mustapha Bature Sallama, Modern Ghana | 06.11.2026
In much of West Africa, a woman who cannot bear children does not merely face a medical condition. She faces a verdict. Her marriage may unravel. Her community may turn cold. Her identity, in a social order that ties womanhood...
By Anna Rogers, Mother Jones | 06.19.2026
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...
